By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Idera Pharmaceuticals, Inc. 

167 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-679-5500 Fax: 617-679-5592


SEARCH JOBS

Idera Pharma develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.

For more information, visit www.iderapharma.com.


Key Statistics


Email: info@iderapharma.com
Ownership: Public

Web Site: Idera Pharma
Employees:
Symbol: IDRA
 









Company News
Idera Pharma (IDRA), Vivelix Pharma Forge $155 Million+ Gastrointestinal R&D Pact 11/28/2016 5:40:28 AM
Idera Pharma (IDRA) Reports Translational Data Supporting The Mechanism Of Action Of Intratumoral IMO-2125 From Ongoing Phase I Dose Escalation In Clinical Trial In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment 11/14/2016 8:38:12 AM
Idera Pharma (IDRA) Reports Third Quarter 2016 Financial Results 10/28/2016 7:58:21 AM
Idera Pharma (IDRA) Announces Pricing Of Public Offering Of Common Stock 10/7/2016 10:29:02 AM
Idera Pharma (IDRA) Announces Proposed Public Offering Of Common Stock 10/6/2016 7:27:07 AM
Idera Pharma (IDRA) Presents New Third Generation Antisense (3GA) Data At The 12th Annual Meeting Of The Oligonucleotide Therapeutics Society 9/27/2016 7:43:09 AM
Idera Pharma (IDRA) Reports Promising Data From Ongoing Phase I Dose Escalation In Clinical Trial Of Intra-Tumoral IMO-2125 In Combination With Ipilimumab In Patients With PD-1 Refractory Metastatic Melanoma 9/26/2016 7:51:20 AM
Idera Pharma (IDRA) Presents The Novel Mechanism Of Action Of Its Third Generation Antisense Technology 8/24/2016 7:45:47 AM
Idera Pharma (IDRA) Reports Second Quarter 2016 Financial Results And Provides Corporate Update 8/2/2016 8:24:19 AM
Idera Pharma (IDRA) Announces Initiation Of Phase I/II Clinical Trial Of Intra-Tumoral IMO-2125 In Combination With Ipilimumab In Patients With Metastatic Melanoma 12/14/2015 7:39:36 AM
12345678910...
//-->